Bank of America Securities Remains a Buy on Sana Biotechnology (SANA)
HC Wainwright & Co. Reiterates Buy on Sana Biotechnology, Maintains $12 Price Target
HC Wainwright & Co. analyst Emily Bodnar reiterates Sana Biotechnology (NASDAQ:SANA) with a Buy and maintains $12 price target.
Sana Biotechnology Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/09/2024 59.36% HC Wainwright & Co. → $12 Reiterates Buy → Buy 03/01/2024 99.21% JMP Securities $8 → $15
Sana Biotechnology Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Sana Biotechnology Shares Are Trading Lower After the Company Reported Q1 Financial Results.
Novo Nordisk, Flagship to Develop Next-generation Obesity Drugs
Sana Biotechnology: Promising Clinical Studies and Breakthrough Potential in T1D Therapy
Buy Rating Affirmed for Sana Biotechnology Amidst Strong Clinical Progress and Solid Financials
Sana Biotechnology Q1 Adj $(0.32), Inline
Sana Biotechnology (NASDAQ:SANA) reported quarterly losses of $(0.32) per share which met the analyst consensus estimate. This is a 25.58 percent increase over losses of $(0.43) per share from the sam
Sana Biotechnology | 10-Q: Quarterly report
Press Release: Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates
Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmu
Sana Biotechnology to Present at May and June 2024 Investor Conferences
SEATTLE, May 06, 2024 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations
Sana Biotechnology EVP and President of R&D Resigns
CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)
Flagship Pioneering Named to Fast Company's Annual List of the World's Most Innovative Companies of 2024
Institutional Investors May Overlook Sana Biotechnology, Inc.'s (NASDAQ:SANA) Recent US$119m Market Cap Drop as Long-term Gains Remain Positive
Key Insights Given the large stake in the stock by institutions, Sana Biotechnology's stock price might be vulnerable to their trading decisions 50% of the business is held by the top 6 shareholders
Director Patrick Yang Sells 25,000 Shares of Sana Biotechnology Inc (SANA)
Sana Biotechnology(SANA.US) Director Sells US$236.3K in Common Stocks
$Sana Biotechnology(SANA.US)$ Director Yang Patrick Y sold 25,000 shares of Common Stocks on Mar 8, 2024 at an average price of $9.452 for a total value of $236.3K.Source: Announcement What is stateme
Baillie Gifford Bolsters Stake in Sana Biotechnology Inc
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities.
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. Shares of Tesla, Inc. (NASDAQ:TSLA) fell during Monday's session after the company reportedly saw a decline in Fe
No Data